Tyme Technologies Inc. (TYME)

[mcsharkey]

Damn. Hope you're having a great weekend.

I was waiting for last Monday's white paper release with extended data on our Prostate Cancer Phase II Therapy report for some REAL ACTION.

Disappointed by non-reactionis is a suitable discription for my mood now
Ain't wrist slitting. The report somes out to 10 pages, 9-anda-half of them are way above my pay grade.
Ain't wrist slitting. The report somes out to 10 pages, 9-anda-half of them are way above my pay grade.

Market didn't understand them either (yeah, that must be it:).

Nuthin' else news worthy to comment on, real dull week. Got some data For Info Only.

At this time, we still have four actions to be completed from page 5 of the 26 August Corporate Presentation for our FY21 Milestones. Orphan Drug designation for Pancreatic Cancer Project added in this latest slide show. That's checked off immediately. These six milestones now remain for FY21, which ends on 31 March..

Any one of these are likely to be our NEXT BIG ANNOUNCEMENT, that might move us out of this cellar.
******************************************************************
...(1) Advance SM-88 clinical programs into other tumor types potentially including metastatic breast, recurrent prostate and/or hematological cancers

...(2) Present and/or publish final data from Part 1 of TYME-88-Panc study.

...(3) Complete enrollment in HopES Sarcoma study

...(4) Complete enrollment in TYME-88-Panc pivotal study (collaborating with PANCAN

...(5) Complete TYME-19 proof of concept.
*****************************************************************
I sent off an RFI on our TYME-19 Proof of Concept progress to Brian Gill, our Investor Relations rep, and got a reply for TYME-19 COVID remedy project cause I think this an immediate game changer.
*****************************************************************
Brian,
Following FDA site page hasn't been updated since August 28th. But there is a huge amount of development projects being pursued throughout the international pharmaceutical industry.

https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap#dashboard

Hoping you may provide as much insight as you may on TYME-19's POC paperwork and TYME's participation with FDA's Coronavirus Treatment Acceleration Program (CTAP), and permission to share your response.
Very Respectfully,
.....*******************************
Brian Gill
11:22 AM (5 hours ago)
Hi Mike, We are waiting on site approvals at Mass General and Weill Cornell. We believe the trials should start in Q4.
R/
Brian
******************************************
Everybodie's lost interest in us this week. The excessively HIGH VOLUME from our TYME-19 announcement (26 August) continues to factor into our daily average which is 1,300,000 shares per day.

Just a skewing factor in the Day Trader's Days-To-Cover, reducing it to 3.2 days. There is some day trading, IMHO, probably STRADDLING options, high premium, thus our TRADING SIDEWAYS around $1 pattern.

******Sept Retail Sales to Date
Sept|Week|
Date| Day |Clsi|Vol
01st|Tues|0.985 |2,133,500
02nd|Wed|1.04..|1,180,500
03d.|Thrs|1.04..|..841,300..
04th| Fri. |1.04..|..835,000..
08th|Tues|1.02..|..510,900..
09th|Wed|1.01..|..564,200..
10th|Thrs|1.01..|..253,100.
11th|Fri. |0.979 |..458,600..
14th|Mon.|1.04..|..475,000..
15th|Tues|1.03..|..316,300..
16th|Wed|1.01..|..294,800..
17th|Thrs|1.02..|..189,400..
18th|Fri. |1.015 |..275,303..
Average Volume for Month 640,580..vs. late Aug and Sept-to-date of 1,300,000.

Coming up to the close of the 2nd quarter (30 September). Within Clinical Trials.gov our self-sponsored NCT03512756* trial is listed as ending in December (A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer PANC).
https://clinicaltrials.gov/ct2/results?cond=&term=sm-88&cntry=&state=&city=&dist=&number=Link

We already have TYME-19 (COVID) out to January-->March for Proof-of-Concept action. Two open slots for breaking news are the Ewings Sarcoma Project and expanding SM-88 and SM-18 projects out to other cancers.

GLTUA
Less